UCD19 CAR T Therapy in Adults With B-ALL and MRD Positivity in CR1

This study is testing a personalized immune cell therapy called CAR T-cell therapy (UCD19) for adults with B-cell acute lymphoblastic leukemia (B-ALL) who have achieved remission after chemotherapy but still have trace amounts of leukemia cells detectable by sensitive tests. These remaining cancer cells (called minimal residual disease, or MRD) increase relapse risk, and this therapy aims to eliminate them. **You may be eligible if:** - You are 18 years or older - You have B-cell ALL and are in your first complete remission after chemotherapy - Sensitive tests (flow cytometry or DNA sequencing) show trace cancer cells still remain - Your general health is good enough for the treatment (ECOG score 0–2) - Your heart, liver, and kidney function meet minimum requirements **You may NOT be eligible if:** - You have active leukemia or have not achieved remission - You have a history of certain brain or nervous system diseases - You are currently pregnant or breastfeeding - You have uncontrolled infections or autoimmune diseases Talk to your doctor to see if this trial is right for you.